Titlebook: HCV: The Journey from Discovery to a Cure; Volume I Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 HCV genome.Molecular Vir

Truculent

The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevirt of this disease, offering patients an excellent chance for a complete cure. Starting from inhibitors incorporating oxime-based P*-shelf moieties, a collaborative effort between Abbott Laboratories and Enanta Pharmaceuticals generated ABT-450 (paritaprevir, a component of Technivie? and Viekira Pak

裹住

Discovery and Development of the Next-Generation HCV NS3 Protease Inhibitor Glecaprevirs a component of two FDA-approved IFN-free DAA combination therapies (Viekira Pak? and Technivie?) with approval to treat genotypes 1 and 4, respectively. However, its activity against some key resistant mutants and other HCV genotypes was limited. This chapter reviews our further effort to identify

同位素

https://doi.org/10.1057/9781137339096nt of robust cell culture systems that were suitable for drug development, but also to study the individual steps of the HCV replication cycle. Here we summarize the step-by-step establishment of HCV cell culture systems with a focus on the replicon system that played a major role in the development of HCV-specific direct-acting antiviral drugs.

剝削

欄桿

Hypopnea

闡明

Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitorson. Potency, selectivity, and other drug-like properties were substantially optimized, and consequently more than a dozen compounds were advanced into preclinical and clinical evaluations. In the end, a prodrug of 2′-fluoro-2′-.-methyluridine monophosphate PSI-7977 (GS-7977, sofosbuvir) was approved for the treatment of chronic HCV infection.

處理

The Discovery and Development of HCV NS3 Protease Inhibitor Paritaprevir?), incorporating novel P*-phenanthridine and P3-amide capping groups and pharmacokinetically boosted by ritonavir. The discovery and development of ABT-450 enabled one of the first IFN-free combination therapies for HCV genotype 1 infection and contributed to the transformation of the treatment of this chronic and deadly disease.

Entrancing

1862-2461 of HCV research that contributed to the development of key dHepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, an

leniency

Book 2019 major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting ant